Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex With Men (DaDHS)
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Syphilis is a sexually transmitted infection (STI) disproportionately affecting gay, bisexual
and other men who have sex with men (gbMSM), with the potential for significant sequelae -
particularly in those who are Human Immunodeficiency Virus (HIV)-positive. Rising rates of
this STI have prompted a search for novel prevention solutions. A recent pilot study of daily
doxycycline prophylaxis demonstrated promise as a novel STI prevention tool. This innovative
approach to STI prevention has solid clinical precedent, both from the HIV pre-exposure
prophylaxis (PrEP) literature, as well as doxycycline's use as prophylaxis for other
infections. The overarching goal of this project is to determine whether the daily use of
doxycycline is an efficacious and acceptable intervention for syphilis prevention in
high-risk, HIV-positive gbMSM.